From the Medical Director

Gerard Sanacora

Depression remains one of the most common and debilitating medical problems throughout the world. Unfortunately, up to one-third of people suffering from depression receive little benefit from the currently available, FDA-approved antidepressants. This is likely to be due to the fact that nearly all of the current medications were developed out of the same pathophysiological model of depression that targets the same monoamine neurotransmitter systems (i.e. serotonin, norepinephrine, and dopamine).

The rapidly expanding field of neuroscience now provides us with a more complete understanding of the neurobiological processes that contribute to depression and other neuropsychiatric disorders. This new information suggests many novel unexplored targets for the development of novel diagnostic and treatment strategies.

At the Yale Depression Research Program, we are committed to advancing our ability to understand, diagnose, and treat depression through innovative research. Ultimately, we hope these studies will lead to improved treatment outcomes, higher remission rates, and an improved quality of life for those individuals suffering from this disorder.